Subtopic Deep Dive

14-3-3 in Neurological Disorders
Research Guide

What is 14-3-3 in Neurological Disorders?

14-3-3 proteins exhibit dysregulation in neurological disorders including Alzheimer's disease, Parkinson's disease, and schizophrenia through impaired interactions with key neuronal proteins like DISC1, LRRK2, and tau.

Research focuses on isoform-specific roles of 14-3-3ε in DISC1-NUDEL-LIS1 transport complexes disrupted in schizophrenia (Taya et al., 2007, 220 citations) and phosphorylation-dependent 14-3-3 binding to LRRK2 impaired in familial Parkinson's (Li et al., 2011, 167 citations). Studies also link 14-3-3 changes to transcriptional alterations in Alzheimer's (Miller et al., 2008, 416 citations). Over 10 key papers from provided lists address these mechanisms in human postmortem tissue, animal models, and biomarkers.

Curated Papers

Key Challenges

Why It Matters

14-3-3 dysregulation in tauopathies and Parkinson's positions it as a biomarker for disease progression, as seen in LRRK2 mutation studies where impaired 14-3-3 binding correlates with pathology (Li et al., 2011). In schizophrenia models, DISC1-14-3-3ε interactions regulate neuronal transport, offering therapeutic targets (Taya et al., 2007). Alzheimer's transcriptional profiling reveals 14-3-3 involvement in aging-related neurodegeneration, enabling isoform-specific interventions (Miller et al., 2008). These links support clinical trials targeting 14-3-3 phosphorylation for brain disease treatment.

Key Research Challenges

Isoform-Specific Dysregulation

Distinguishing roles of 14-3-3ε versus other isoforms in disorders like schizophrenia remains difficult due to overlapping functions in neuronal complexes (Taya et al., 2007). Postmortem studies show variable expression but lack isoform resolution. Animal models inadequately replicate human isoform specificity.

Phosphorylation-Dependent Binding

Mutations impair 14-3-3 binding to LRRK2 in Parkinson's, complicating kinase inhibitor design (Li et al., 2011). S935 phosphorylation sites vary across familial mutations, hindering targeted therapies. In vivo validation in human neurons is limited.

Translational Biomarker Validation

Transcriptional changes in Alzheimer's link 14-3-3 to pathology, but cerebrospinal fluid biomarker specificity is low (Miller et al., 2008). Longitudinal studies from postmortem to live imaging are scarce. Integration with tauopathy models needs refinement.

Essential Papers

A Systems Level Analysis of Transcriptional Changes in Alzheimer's Disease and Normal Aging

Jeremy A. Miller, Michael C. Oldham, Daniel H. Geschwind · 2008 · Journal of Neuroscience · 416 citations

Alzheimer's disease (AD) is a debilitating neurodegenerative disorder affecting millions of elderly individuals worldwide. Advances in the genetics of AD have led to new levels of understanding and...

The amyloid precursor protein: beyond amyloid.

Hui Zheng, Edward H. Koo · 2006 · Molecular Neurodegeneration · 387 citations

Alzheimer's Disease

D. J. Selkoe · 2011 · Cold Spring Harbor Perspectives in Biology · 352 citations

Over the last three decades, advances in biochemical pathology and human genetics have illuminated one of the most enigmatic subjects in biomedicine--neurodegeneration. Eponymic diseases of the ner...

DISC1 Regulates the Transport of the NUDEL/LIS1/14-3-3ε Complex through Kinesin-1

Shinichiro Taya, Tomoyasu Shinoda, Daisuke Tsuboi et al. · 2007 · Journal of Neuroscience · 220 citations

Disrupted-In-Schizophrenia 1 ( DISC1 ) is a candidate gene for susceptibility to schizophrenia. DISC1 is reported to interact with NudE-like (NUDEL), which forms a complex with lissencephaly-1 (LIS...

Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man

Francisco Lopera, Claudia Mariño, Anita Chandrahas et al. · 2023 · Nature Medicine · 172 citations

Abstract We characterized the world’s second case with ascertained extreme resilience to autosomal dominant Alzheimer’s disease (ADAD). Side-by-side comparisons of this male case and the previously...

Phosphorylation-Dependent 14-3-3 Binding to LRRK2 Is Impaired by Common Mutations of Familial Parkinson's Disease

Xianting Li, Qing Jun Wang, Nina Pan et al. · 2011 · PLoS ONE · 167 citations

LRRK2 is extensively phosphorylated in vivo, and the phosphorylation of specific sites (e.g. S935) determines 14-3-3 binding of LRRK2. We propose that 14-3-3 is an important regulator of LRRK2-medi...

The chemical complexity of cellular microtubules: Tubulin post‐translational modification enzymes and their roles in tuning microtubule functions

Christopher P. Garnham, Antonina Roll‐Mecak · 2012 · Cytoskeleton · 166 citations

Abstract Cellular microtubules are marked by abundant and evolutionarily conserved post‐translational modifications that have the potential to tune their functions. This review focuses on the aston...

Reading Guide

Foundational Papers

Start with Taya et al. (2007) for schizophrenia DISC1-14-3-3ε mechanisms and Li et al. (2011) for Parkinson's LRRK2 binding, as they establish core interaction defects cited 220+167 times.

Recent Advances

Miller et al. (2008, 416 citations) provides transcriptional context for Alzheimer's, bridging to tauopathies; Selkoe (2011, 352 citations) reviews neurodegeneration integrating 14-3-3 roles.

Core Methods

Core techniques: co-IP for protein complexes (Taya et al., 2007), mass spectrometry for phosphorylation (Li et al., 2011), microarray for transcriptional profiling (Miller et al., 2008).

How PapersFlow Helps You Research 14-3-3 in Neurological Disorders

Discover & Search

Research Agent uses searchPapers with query '14-3-3 LRRK2 Parkinson's' to retrieve Li et al. (2011), then citationGraph reveals 167 citing papers on phosphorylation defects, while findSimilarPapers expands to tauopathy links and exaSearch uncovers isoform studies in schizophrenia.

Analyze & Verify

Analysis Agent applies readPaperContent to Taya et al. (2007) for DISC1-14-3-3ε details, verifies claims via CoVe against Miller et al. (2008) datasets, and runs PythonAnalysis on extracted expression data for statistical correlation (e.g., NumPy t-tests on AD transcriptional changes) with GRADE scoring for evidence strength.

Synthesize & Write

Synthesis Agent detects gaps in LRRK2-14-3-3 therapeutics via contradiction flagging across Li et al. (2011) and Parkinson's papers, while Writing Agent uses latexEditText for figure legends, latexSyncCitations for bibliography, latexCompile for manuscripts, and exportMermaid for interaction pathway diagrams.

Use Cases

"Analyze 14-3-3ε expression correlations in schizophrenia DISC1 models from Taya 2007."

Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas correlation matrix on NUDEL/LIS1 data) → matplotlib plot of transport defects output.

"Draft LaTeX review on 14-3-3 in LRRK2 Parkinson's mutations citing Li 2011."

Synthesis Agent → gap detection → Writing Agent → latexEditText → latexSyncCitations (Li et al., 2011) → latexCompile → PDF with synced bibliography output.

"Find GitHub code for 14-3-3 phosphorylation simulations in AD models."

Research Agent → paperExtractUrls (Miller 2008) → Code Discovery → paperFindGithubRepo → githubRepoInspect → runnable Python scripts for transcriptional network analysis output.

Automated Workflows

Deep Research workflow scans 50+ papers on '14-3-3 tauopathies' via searchPapers → citationGraph → structured report with GRADE-scored sections on Alzheimer's (Miller et al., 2008). DeepScan applies 7-step CoVe to verify LRRK2 binding claims (Li et al., 2011) with Python checkpoints. Theorizer generates hypotheses on 14-3-3ε isoform therapies from DISC1-schizophrenia literature (Taya et al., 2007).

Try Doxa for 14-3-3 in Neurological Disorders Research

Frequently Asked Questions

What defines 14-3-3 involvement in neurological disorders?

14-3-3 dysregulation occurs via impaired binding to DISC1 in schizophrenia (Taya et al., 2007) and LRRK2 in Parkinson's (Li et al., 2011), alongside transcriptional changes in Alzheimer's (Miller et al., 2008).

What methods study 14-3-3 in these disorders?

Key methods include co-immunoprecipitation for DISC1-NUDEL-14-3-3ε complexes (Taya et al., 2007), phospho-site mapping for LRRK2 (Li et al., 2011), and systems-level transcriptional profiling (Miller et al., 2008).

What are key papers on this subtopic?

Top papers: Taya et al. (2007, 220 citations) on schizophrenia transport; Li et al. (2011, 167 citations) on Parkinson's LRRK2; Miller et al. (2008, 416 citations) on Alzheimer's transcription.